{
  "@context": {
    "biotools": "https://bio.tools/ontology/",
    "bsc": "http://bioschemas.org/",
    "edam": "http://edamontology.org/",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@id": "https://bio.tools/ADAMTS7_E373Q_ADAMTS7_WT_ADAMTS7",
  "@type": "sc:SoftwareApplication",
  "sc:description": "> HOMEPAGE MISSING! | > CORRECT NAME OF TOOL COULD ALSO BE 'E373Q ADAMTS7 WT ADAMTS7 E373Q', 'ADAMTS7 E373Q ADAMTS7', 'Luciferase ADAMTS7 E373Q ADAMTS7', 'ADAMTS7 WT ADAMTS7 E373Q' | Introduction: The identification of corticotropin-releasing hormone (CRH) has led to the discovery of a growing family of ligands and receptors. CRH receptor 1 (CRHR1) and CRHR2 are mammalian G-protein coupled receptors (GPCRs) with high affinity for CRH and the CRH family of peptides. CRHR1 is predominantly expressed in the brain and plays a vital role in the hypothalamic-pituitary-adrenal (HPA) axis stress responses by secreting adrenal corticotropic hormone (ACTH). CRHR2 is predominantly expressed in the periphery and urocortin 2 (UCN2), a CRHR2-specific ligand, has been involved in the regulation of glucose metabolism. Ucn-2, a 38 aa peptide, shows reasonable homology between rat and human CRH (âˆ¼34%), Ucn-1 (43%) and Ucn-3 (37 40%)",
  "sc:name": "ADAMTS7 E373Q ADAMTS7 WT ADAMTS7",
  "sc:url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698788/"
}